Form 8-K - Current report:
SEC Accession No. 0001628280-23-034587
Filing Date
2023-10-18
Accepted
2023-10-18 16:14:37
Documents
15
Period of Report
2023-10-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ardx-20231017.htm   iXBRL 8-K 31865
2 EX-10.1 ardelyx-thirdamendmenttolo.htm EX-10.1 126120
7 ardx-20231017_g1.jpg GRAPHIC 2570
  Complete submission text file 0001628280-23-034587.txt   344766

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20231017.xsd EX-101.SCH 2155
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ardx-20231017_def.xml EX-101.DEF 15269
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20231017_lab.xml EX-101.LAB 29722
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20231017_pre.xml EX-101.PRE 15971
9 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20231017_htm.xml XML 3294
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36485 | Film No.: 231332411
SIC: 2834 Pharmaceutical Preparations